PITCHER (Peritoneal Carcinomatosis Heterogeneity)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04714957|
Recruitment Status : Recruiting
First Posted : January 20, 2021
Last Update Posted : January 20, 2021
How epigenetic deregulation affects gene expression patterns in subclones of the same tumor is poorly known. Peritoneal Carcinomatosis (PC) is a condition in which multiple metastases of the same abdominal tumor develop in the peritoneal cavity and intra-peritoneal organs, thus defining different ecosystems of the same cancer. PITCHER addresses the variations in epigenetically regulated gene expression between different subclones of PC in relation with cell mechanoresponses, providing insights on how cancer epigenetic landscapes evolve under environmental pressures and on strategies used by cancer cells to adapt to the transition from one ecosystem to the other.
PITCHER is a network of 10 teams from Lyon, Grenoble and Marseille, based on data and specimen collection of patients who have undergone a surgery for a peritoneal carcinomatosis of ovarian or colorectal origin. PC lesions and eventually matched specimens of primary tumors will be collected in the same patients at the time of the surgery or eventually retrieved from already existing samples. Epigenetic landscapes will be analyzed by a bioinformatics pipeline combining exome sequencing, transcriptome and methylome to identify "epigenetic hotspots", and their variations across lesions will be evaluated. These analyses will be realized in fresh (when available) or pre-existing samples. When possible, organoid cultures and animal models will be derived from multicellular structures in peritoneal fluids and membrane, cytoskeletal and nucleoskeletal mechanoresponses will be characterized using Atomic Force Microscopy. The role of tumor axonogenesis, a process of neo-formation of axon fibers in tumors, will be addressed. Experimental studies of cell responses to therapy will be performed to derive mathematical predictive models. All components will be integrated in a systems biology map of PC.
|Condition or disease||Intervention/treatment|
|Secondary Peritoneal Cancers Colorectal Cancer Ovarian Cancer||Other: construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||PITCHER (Peritoneal Carcinomatosis Heterogeneity)|
|Actual Study Start Date :||September 1, 2020|
|Estimated Primary Completion Date :||September 2022|
|Estimated Study Completion Date :||September 2027|
- Other: construction of a database of genetic and epigenetic data on peritoneal carcinomatosis of colorectal or ovarian origin.
Construction of a core database of genetic and epigenetic markers, in order to identify predictive biomarkers and potentially actionable targets for controlling the spread of peritoneal carcinomatosis.
- genetic and epigenetic data available for 20 "multiplets" biospecimens (peritoneal carcinomatosis + healthy tissue + primary tumor + tissue from other tumor metastasis - when applicable and available- ) [ Time Frame: end of the inclusion period (September 2022) ]The main endpoint is to implement a specific tissue collection of appropriate quality, assembling "multiplets" of biospecimens from the same patient, in order to construct a core database for research on mechanisms, biomarkers and actionable therapeutic targets in PC. This database will include molecular analysis by next-generation sequencing of whole-exome genetic, transcriptomic and epigenetic patterns of primary, peritoneal and metastatic lesions. "Omics" data are compiled using a data model also including anonymized information on histopathology and clinical history of treatments (when applicable)
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04714957
|Contact: Olivier GLEHEN, MD||+33 4 78 86 23 email@example.com|
|Contact: Sara CALATTINI, CRA||+33 4 78 86 37 firstname.lastname@example.org|
|Lyon SUD Hospital, Hospices Civils de Lyon||Recruiting|
|Contact: Olivier GLEHEN, MD +33 4 78 86 23 71 email@example.com|